<div id="readability-page-1"><div>NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. (&#34;Protagonist&#34; or the &#34;Company&#34;) announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025.ASH Presentation Details: Presenting Author: Andrew Kuykendall, MD (Moffitt Cancer Center) Publication Number: 81 Title: Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study Oral Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome Session Date: Saturday, December 6, 2025 Presentation Time: 10:00 AM - 10:15 AM EST Location: Orlando Convention Center, W414CDPresenting Author: Aniket Bankar, MD (Princess Margaret Cancer Centre) Publication Number: 5588 Title: Comprehensive Analyses of Patient-Reported Outcomes from the Phase 3 VERIFY Study of Rusfertide or Placebo Plus Current Standard of Care for Polycythemia Vera Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III Session Date: Monday, December 8, 2025 Presentation Time: 6:00 PM - 8:00 PM EST Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)Presenting Author: Joseph Shatzel, MD (Oregon Health &amp; Science University) Publication Number: 5587 Title: Should Dermatologic Examinations Become Routine Standard of Care in Patients with Polycythemia Vera, Observations from the Phase 3 VERIFY Study Prior to Rusfertide Exposure Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III Session Date: Monday, December 8, 2025 Presentation Time: 6:00 PM - 8:00 PM EST Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)Presenting Author: Naveen Pemmajaru, MD (MD Anderson Cancer Center) Publication Number: 3810 Title: Long-term Rusfertide Treatment in Polycythemia Vera: Initial Results from the Phase 2 THRIVE Extension Study Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II Session Date: Sunday, December 7, 2025 Presentation Time: 6:00 PM - 8:00 PM EST Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and in the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (&#34;IL-23R&#34;) which is licensed to Janssen Biotech, Inc., a Johnson &amp; Johnson company, Inc. Following icotrokinra's joint discovery by Protagonist and Johnson &amp; Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson &amp; Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 cdavis@lifesciadvisors.comMedia Relations Contact Virginia Amann ENTENTE Network of Companies virginiaamann@ententeinc.com +1 833 500 0061SOURCE: Protagonist TherapeuticsView the original press release on ACCESS Newswire <img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA5NjQ4MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA5NjQ4MA"/></div></div>

4502

強生

Protagonist Therapeutics, Inc. 宣佈將在 2025 年 12 月 6 日至 9 日於佛羅里達州奧蘭多舉行的第 67 屆年度 ASH 會議上進行四場關於 rusfertide 的報告。這些報告將重點關注來自第三階段 VERIFY 研究的臨牀數據，涉及 rusfertide 在治療真性紅細胞增多症方面的療效和安全性。值得注意的報告包括由 Andrew Kuykendall 博士進行的口頭報告，以及幾場海報展示，內容涉及患者報告的結果和長期治療效果的分析。Protagonist 正在推進其藥物開發管線，包括 rusfertide 和 icotrokinra，並與武田製藥和強生公司合作

Protagonist Therapeutics 宣佈將在第 67 屆 ASH 年會上進行 Rusfertide 的口頭報告和海報展示